JP7796230B2 - Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体 - Google Patents

Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体

Info

Publication number
JP7796230B2
JP7796230B2 JP2024535848A JP2024535848A JP7796230B2 JP 7796230 B2 JP7796230 B2 JP 7796230B2 JP 2024535848 A JP2024535848 A JP 2024535848A JP 2024535848 A JP2024535848 A JP 2024535848A JP 7796230 B2 JP7796230 B2 JP 7796230B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
cells
drug conjugate
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024535848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546497A (ja
JP2024546497A5 (https=
Inventor
カイチエ フー
ショアイシアン チョウ
シャオダン リウ
ジャア ルー
Original Assignee
フォートビタ バイオロジクス（シンガポール）プライベート リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フォートビタ バイオロジクス（シンガポール）プライベート リミティド filed Critical フォートビタ バイオロジクス（シンガポール）プライベート リミティド
Publication of JP2024546497A publication Critical patent/JP2024546497A/ja
Publication of JP2024546497A5 publication Critical patent/JP2024546497A5/ja
Priority to JP2025271167A priority Critical patent/JP2026053502A/ja
Application granted granted Critical
Publication of JP7796230B2 publication Critical patent/JP7796230B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024535848A 2021-12-17 2022-12-16 Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体 Active JP7796230B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025271167A JP2026053502A (ja) 2021-12-17 2025-12-22 Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111551337 2021-12-17
CN202111551337.8 2021-12-17
PCT/CN2022/139637 WO2023109953A1 (zh) 2021-12-17 2022-12-16 靶向Claudin18.2的抗体-药物偶联物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025271167A Division JP2026053502A (ja) 2021-12-17 2025-12-22 Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体

Publications (3)

Publication Number Publication Date
JP2024546497A JP2024546497A (ja) 2024-12-24
JP2024546497A5 JP2024546497A5 (https=) 2025-11-11
JP7796230B2 true JP7796230B2 (ja) 2026-01-08

Family

ID=86774867

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024535848A Active JP7796230B2 (ja) 2021-12-17 2022-12-16 Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体
JP2025271167A Pending JP2026053502A (ja) 2021-12-17 2025-12-22 Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025271167A Pending JP2026053502A (ja) 2021-12-17 2025-12-22 Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体

Country Status (9)

Country Link
US (1) US20250073347A1 (https=)
EP (1) EP4450521A1 (https=)
JP (2) JP7796230B2 (https=)
KR (1) KR20240133715A (https=)
CN (1) CN119173534A (https=)
AU (1) AU2022416272A1 (https=)
CA (1) CA3242970A1 (https=)
TW (1) TWI869741B (https=)
WO (1) WO2023109953A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7796230B2 (ja) * 2021-12-17 2026-01-08 フォートビタ バイオロジクス（シンガポール）プライベート リミティド Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
CN119591708A (zh) * 2023-09-08 2025-03-11 成都临界点生物科技有限公司 抗Claudin18.2人源化单域抗体
WO2025077815A1 (zh) * 2023-10-11 2025-04-17 福佑泰生物制药（新加坡）公司 靶向Claudin18.2的抗体-药物偶联物联合治疗癌症的方法
TW202532100A (zh) * 2023-12-22 2025-08-16 大陸商信達生物製藥（蘇州）有限公司 靶向b7h3和egfr的雙特異性抗體-藥物偶聯物及其應用
WO2025149029A1 (zh) * 2024-01-12 2025-07-17 信达生物制药(苏州)有限公司 抗cd28抗体及其用途
CN119345386B (zh) * 2024-10-25 2025-12-09 华润生物医药有限公司 靶向Claudin18.2的抗体药物耦联物及其用途
CN121130103A (zh) * 2025-11-05 2025-12-16 上海以岭药业有限公司 靶向cldn 18.2的抗体药物偶联物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112138171A (zh) 2019-06-28 2020-12-29 上海复旦张江生物医药股份有限公司 抗体偶联药物、其中间体、制备方法及应用
WO2021008463A1 (zh) 2019-07-12 2021-01-21 明济生物制药（北京）有限公司 Cldn18.2抗体及其用途
CN112707965A (zh) 2019-09-30 2021-04-27 和铂医药(苏州)有限公司 靶向cldn18.2的抗体及其制备方法和应用
WO2021115426A1 (zh) 2019-12-12 2021-06-17 江苏恒瑞医药股份有限公司 抗密蛋白抗体药物偶联物及其医药用途
WO2021254481A1 (zh) 2020-06-19 2021-12-23 信达生物制药(苏州)有限公司 抗Claudin18.2抗体以及其用途
WO2022058395A1 (en) 2020-09-15 2022-03-24 Synaffix B.V. Antibody-exatecan conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701753B2 (en) * 2013-03-11 2017-07-11 Genzyme Corporation Hyperglycosylated binding polypeptides
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
NZ762505A (en) * 2017-09-29 2026-03-27 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
WO2019242505A1 (zh) * 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
SG11202106765XA (en) * 2018-12-27 2021-07-29 Gigagen Inc Anti-pd-1 binding proteins and methods of use thereof
CN119350498A (zh) * 2018-12-28 2025-01-24 四川科伦博泰生物医药股份有限公司 一种抗体及其用途
CN113631229B (zh) * 2019-03-25 2025-09-23 第一三共株式会社 抗体－吡咯并苯并二氮杂卓衍生物偶联物
US20240293457A1 (en) * 2020-12-25 2024-09-05 Innovent Biologics (Suzhou) Co., Ltd. Claudin18.2 chimeric antigen receptor and use thereof
JP7796230B2 (ja) * 2021-12-17 2026-01-08 フォートビタ バイオロジクス（シンガポール）プライベート リミティド Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112138171A (zh) 2019-06-28 2020-12-29 上海复旦张江生物医药股份有限公司 抗体偶联药物、其中间体、制备方法及应用
WO2021008463A1 (zh) 2019-07-12 2021-01-21 明济生物制药（北京）有限公司 Cldn18.2抗体及其用途
CN112707965A (zh) 2019-09-30 2021-04-27 和铂医药(苏州)有限公司 靶向cldn18.2的抗体及其制备方法和应用
WO2021115426A1 (zh) 2019-12-12 2021-06-17 江苏恒瑞医药股份有限公司 抗密蛋白抗体药物偶联物及其医药用途
WO2021254481A1 (zh) 2020-06-19 2021-12-23 信达生物制药(苏州)有限公司 抗Claudin18.2抗体以及其用途
WO2022058395A1 (en) 2020-09-15 2022-03-24 Synaffix B.V. Antibody-exatecan conjugates

Also Published As

Publication number Publication date
CN119173534A (zh) 2024-12-20
EP4450521A1 (en) 2024-10-23
CA3242970A1 (en) 2023-06-22
TW202333798A (zh) 2023-09-01
AU2022416272A1 (en) 2024-07-18
TWI869741B (zh) 2025-01-11
WO2023109953A9 (zh) 2023-07-27
JP2026053502A (ja) 2026-03-25
US20250073347A1 (en) 2025-03-06
JP2024546497A (ja) 2024-12-24
WO2023109953A1 (zh) 2023-06-22
KR20240133715A (ko) 2024-09-04

Similar Documents

Publication Publication Date Title
JP7796230B2 (ja) Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体
JP7440122B2 (ja) Ｃｌｄｎ１８．２抗体及びその用途
Sawada et al. Human monoclonal antibodies to sialyl-Lewisa (CA19. 9) with potent CDC, ADCC, and antitumor activity
US12441795B2 (en) Anti-ROR1 antibodies and preparation method and uses thereof
JP2021000132A (ja) 抗ｍｕｃ１６抗体及びその使用
JP2022008618A (ja) Ｍｕｃ１に特異的に結合する抗体及びその用途
AU2021353368B2 (en) Anti-cd3 antibody and uses thereof
JP2024525624A (ja) 抗体薬物コンジュゲート及びその使用
CN112390885A (zh) 一种trop2抗体及其制备方法、其偶联物和应用
JP2024514855A (ja) Ｄｌｌ３に対する結合分子及びその使用
JP2021509105A (ja) ＥＧＦＲｖＩＩＩ抗体ならびにその複合体、製造方法および使用
JP2017506640A (ja) 細胞外標的化薬物共役体
CN121177510A (zh) 抗cea抗体药物缀合物和使用方法
EP2270053A1 (en) Humanized AXL antibodies
WO2025214486A1 (zh) 抗Trop2抗体和抗5T4抗体-自然杀伤细胞偶联物及其用途
TWI910674B (zh) 包含靶向claudin 18.2的抗體-藥物偶聯物的製劑及其製備方法和用途
JP7811028B2 (ja) ヒトｃｘｃｌ１６抗体およびその使用
HK1198654A1 (en) Recombinant antibodies having dual specificity for gangliosides and use thereof
WO2025131053A1 (en) Bispecific antibody-drug conjugates targeting b7h3 and egfr and the use thereof
CN119345386B (zh) 靶向Claudin18.2的抗体药物耦联物及其用途
WO2025228330A1 (en) Antibodies targeting dll3 and antibody-drug conjugates and uses thereof
WO2024131835A1 (en) Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof
HK40128448A (zh) 靶向b7h3和egfr的双特异性抗体-药物偶联物及其应用
HK40120055A (zh) 包含靶向claudin18.2的抗体-药物偶联物的制剂及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251031

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251222

R150 Certificate of patent or registration of utility model

Ref document number: 7796230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04